Other languages Elicera Therapeutics AB

Equities

ELIC

SE0015382080

Market Closed - Nasdaq Stockholm Other stock markets 11:08:49 2024-05-03 am EDT			5-day change	1st Jan Change
0.93 ^SEK	-2.11%		-2.11%	-79.61%

Mar. 28	Elicera Therapeutics AB Announces Director Changes	CI
Mar. 06	Elicera Enters Agreement with Prominent US Cancer Center to Evaluate the Use of ITANK in T-Cell Receptor Therapies	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Elicera Therapeutics AB Announces Director Changes	Mar. 28
Elicera Enters Agreement with Prominent US Cancer Center to Evaluate the Use of ITANK in T-Cell Receptor Therapies	Mar. 06
Elicera Therapeutics AB to Present at the Scientific Conference International Society for Cell & Gene Therapy Meeting 2024 in Vancouver, Canada, May 28 to June 1	Feb. 16
Elicera Therapeutics AB Receives Conditional Approval from the Medical Products Agency on Its Car T-Cell Clinical Trial Application to Test ELC-301	Feb. 14
Elicera Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 13
Elicera Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 13
Elicera Therapeutics Receives Approval to Initiate Clinical Phase I/II-Study Carma with Car T-Cell Therapy ELC-301 in B-Cell Lymphoma	Feb. 09
Elicera Therapeutics AB Participates in A Collaborative Project for the Development of Improved Car T-Cell Production That Has Been Awarded Research Support of SEK 850 Thousand	Jan. 09
Elicera Therapeutics AB Co-Founder Receives Grant Totalling 4.8 million SEK from the Swedish Childhood Cancer Fund to Support Car T-Cell Research	Dec. 22
Elicera Therapeutics AB Submits GMP Validation Data to the Swedish Medical Products Agency for the CARMA Study to Supplement the Conditionally Approved Clinical Trial Application	Dec. 22
Elicera Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Elicera Therapeutics AB Announces That Representatives of the Largest Owners Appoints the Nomination Committee Ahead of the Annual General Meeting 2024	23-10-31
Elicera Therapeutics Receives Notice of Allowance for Chinease Patent Protecting the iTANK Platform	23-09-08
Elicera Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-29
Elicera Therapeutics AB Announces the Publication of a Scientific Article in the ELC-401 Program	23-08-10
Elicera Therapeutics AB Receives Notice of Allowance for European Patent Protecting the iTANK	23-07-11
Elicera Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-16
Elicera Therapeutics AB Receives Conditional Approval from the Medical Products Agency on its CAR T-Cell Clinical Trial Application to Test ELC-301 (CARMA- Study)	23-04-28
Elicera Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-17
Elicera Therapeutics AB Submits Clinical Trial Application to Evaluate Its CAR T-Cell Therapy in B-Cell Lymphoma	23-01-26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Elicera Therapeutics AB

Equities

ELIC

SE0015382080

Other languages

Filters